BIOEXTRAX AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.335 SEK | -3.51% |
|
+7.36% | -23.06% |
| 16/02 | Bioextrax AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 16/02 | Bioextrax AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 |
|---|---|---|---|
| Capitalization 1 | 246.8 | 938 | 87.59 |
| Enterprise Value (EV) 1 | 244.7 | 929 | 60.06 |
| P/E ratio | -41.2 x | -86 x | -3.11 x |
| Yield | - | - | - |
| Capitalization / Revenue | 1,113 x | 912 x | 39.8 x |
| EV / Revenue | 1,103 x | 903 x | 27.3 x |
| EV / EBITDA | -45.3 x | -91.3 x | -3.3 x |
| EV / FCF | -100 x | -169 x | -3.46 x |
| FCF Yield | -1% | -0.59% | -28.9% |
| Price to Book | 149 x | 125 x | 2.76 x |
| Nbr of stocks (in thousands) | 12,655 | 14,749 | 25,462 |
| Reference price 2 | 19.50 | 63.60 | 3.440 |
| Announcement Date | 07/06/21 | 03/06/22 | 05/05/23 |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Net sales 1 | 0.6897 | 1.383 | 0.2218 | 1.029 | 2.198 |
| EBITDA 1 | -0.8525 | -1.874 | -5.396 | -10.18 | -18.19 |
| EBIT 1 | -0.885 | -1.988 | -5.569 | -10.53 | -18.67 |
| Operating Margin | -128.32% | -143.75% | -2,511% | -1,023.1% | -849.27% |
| Earnings before Tax (EBT) 1 | -0.8871 | -1.989 | -5.572 | -10.53 | -18.67 |
| Net income 1 | -0.8871 | -1.989 | -5.572 | -10.53 | -18.67 |
| Net margin | -128.62% | -143.84% | -2,512.28% | -1,023.42% | -849.27% |
| EPS | - | -0.1986 | -0.4729 | -0.7393 | -1.105 |
| Free Cash Flow 1 | 0.7375 | -3.036 | -2.437 | -5.502 | -17.38 |
| FCF margin | 106.93% | -219.57% | -1,098.99% | -534.69% | -790.8% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 27/05/20 | 27/05/20 | 07/06/21 | 03/06/22 | 05/05/23 |
1SEK in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | 1.44 | 0.58 | 2.05 | 8.98 | 27.5 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | 0.74 | -3.04 | -2.44 | -5.5 | -17.4 |
| ROE (net income / shareholders' equity) | -365% | -261% | -386% | -230% | -95.1% |
| ROA (Net income/ Total Assets) | -50.6% | -71.9% | -146% | -84% | -46.2% |
| Assets 1 | 1.753 | 2.767 | 3.819 | 12.54 | 40.45 |
| Book Value Per Share | - | 0.1200 | 0.1300 | 0.5100 | 1.250 |
| Cash Flow per Share | - | 0.0600 | 0.1600 | 0.6100 | 1.080 |
| Capex 1 | 0.12 | 0.61 | 0.15 | 0.98 | 6.78 |
| Capex / Sales | 16.79% | 44.18% | 68.09% | 94.76% | 308.28% |
| Announcement Date | 27/05/20 | 27/05/20 | 07/06/21 | 03/06/22 | 05/05/23 |
1SEK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -23.06% | 6.21M | |
| -26.95% | 219M | |
| +37.03% | 75.69M | |
| -23.50% | 65.41M |
- Stock Market
- Equities
- BIOEX Stock
- Financials Bioextrax AB
